Abstract: A method of desulfurizing a lean NOx trap (LNT) of an exhaust purification system provided with the LNT and a selective catalytic reduction (SCR) catalyst includes determining whether a desulfurization feasibility condition of the LNT is satisfied, determining whether a desulfurization demand condition of the LNT is satisfied, and performing desulfurization of the LNT if both of the desulfurization feasibility condition of the LNT and the desulfurization demand condition of the LNT are satisfied, wherein the desulfurization of the LNT is performed by repeating a desulfurization lean mode and a desulfurization rich mode according to whether a mode switching condition due to a desulfurization temperature is satisfied and whether a mode switching condition due to generation of H2S is satisfied.

Abstract: The present invention relates to a selection method of a highly active stem cell for treatment of cerebrovascular diseases, comprising a step of measuring a level of a neurotrophic factor, and a highly active stem cell selected thereby. According to the present invention, BDNF secreted by mesenchymal stem cells mediate inhibitory effects on cell death, inflammation, astrogliosis, and posthemorrhagic hydrocephalus and plays a very important role in improving myelination after intraventricular hemorrhage. Hence, the method according to the present invention can be usefully applied to the treatment of various cerebrovascular diseases including intraventricular hemorrhage in preterm infants.

Abstract: The present invention relates to a pharmaceutical composition for treating cerebrovascular diseases including stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention have superior nerve cell protective effects, such as inhibition of cerebral ventricular distention, reduction of hydrocephalus, and inhibition of nerve cell death and cellular inflammation in an intraventricular hemorrhage (IVH) animal model, and thus, can be useful in treating cerebrovascular diseases including intraventricular hemorrhage, etc.

Abstract: A sealed honeycomb structure may include porous walls dividedly forming inlet cells and outlet cells extending from an end surface of an inlet side to an end surface of an outlet side, inlet and outlet side sealing portion 5b, and an inlet side sealing portion, wherein at least one outlet cell is a reinforced cell where a reinforcing part 6 for reinforcing the outlet cell 2b is formed at at least one corner portion 21a at which the walls on a cross-section vertical to an extending direction of the cell cross each other, wherein the inlet cell is a non-reinforced cell where the reinforcing part is not formed at all the corner portions at which the walls on the cross-section vertical to the extending direction of the cell cross each other, and wherein the reinforcing parts 6 of the reinforced cells 22 are formed at a section of the honeycomb structure from the end surface of the outlet side in the extending direction of the cell.

Abstract: A sealed honeycomb structure may include porous walls dividedly forming inlet cells and outlet cells extending from an end surface of an inlet side to an end surface of an outlet side, inlet and outlet side sealing portion 5b, and an inlet side sealing portion, wherein at least one outlet cell is a reinforced cell where a reinforcing part 6 for reinforcing the outlet cell 2b is formed at at least one corner portion 21a at which the walls on a cross-section vertical to an extending direction of the cell cross each other, wherein the inlet cell is a non-reinforced cell where the reinforcing part is not formed at all the corner portions at which the walls on the cross-section vertical to the extending direction of the cell cross each other, and wherein the reinforcing parts 6 of the reinforced cells 22 are formed at a section of the honeycomb structure from the end surface of the outlet side in the extending direction of the cell.

Abstract: The present invention relates to a method of promoting generation of exosomes from stem cell by using thrombin. The method according to the present invention has superior effects of promoting generation of stem cell-derived exosomes and thus exosomes can be more efficiently obtained thereby compared to conventionally known methods. In addition, the method can be useful for related research.

Abstract: The present invention relates to a composition for treating inflammatory brain diseases, which includes stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention can be usefully applied to the treatment of inflammatory brain diseases, because the exosomes have outstanding therapeutic effects, including inhibiting cell death due to inflammation in nerve cells, increasing the survival rate in an inflammatory-brain-disease animal model, and substantially reducing brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema.

Abstract: A catalytic converter for a vehicle includes an LNT converter into one side of which exhaust gas discharged from an engine flows and from the opposite side of which the exhaust gas. The LNT converter traps nitrogen oxide contained in the exhaust gas under a lean environment, desorbs the trapped nitrogen oxide under a rich environment, and reduces the nitrogen oxide contained in the exhaust gas or the desorbed nitrogen oxide. A connecting housing changes a direction of a path of the exhaust gas to a vertical direction, and allows a reducing agent to be injected to the exhaust gas. An SDPF converter changes a direction of a path of the exhaust gas to a direction opposite to a direction, captures particulate matters contained in the exhaust gas, and reduces nitrogen oxide contained in the exhaust gas using the injected reducing agent.

Abstract: A sealed honeycomb structure may include porous walls dividedly forming inlet cells and outlet cells extending from an end surface of an inlet side to an end surface of an outlet side, inlet and outlet side sealing portion 5b, and an inlet side sealing portion, wherein at least one outlet cell is a reinforced cell where a reinforcing part 6 for reinforcing the outlet cell 2b is formed at at least one corner portion 21a at which the walls on a cross-section vertical to an extending direction of the cell cross each other, wherein the inlet cell is a non-reinforced cell where the reinforcing part is not formed at all the corner portions at which the walls on the cross-section vertical to the extending direction of the cell cross each other, and wherein the reinforcing parts 6 of the reinforced cells 22 are formed at a section of the honeycomb structure from the end surface of the outlet side in the extending direction of the cell.

Abstract: A sealed honeycomb structure may include porous walls dividedly forming inlet cells and outlet cells extending from an end surface of an inlet side to an end surface of an outlet side, inlet and outlet side sealing portion 5b, and an inlet side sealing portion, wherein at least one outlet cell is a reinforced cell where a reinforcing part 6 for reinforcing the outlet cell 2b is formed at at least one corner portion 21a at which the walls on a cross-section vertical to an extending direction of the cell cross each other, wherein the inlet cell is a non-reinforced cell where the reinforcing part is not formed at all the corner portions at which the walls on the cross-section vertical to the extending direction of the cell cross each other, and wherein the reinforcing parts 6 of the reinforced cells 22 are formed at a section of the honeycomb structure from the end surface of the outlet side in the extending direction of the cell.

Abstract: The present invention relates to a composition for treating inflammatory brain diseases, which includes stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention can be usefully applied to the treatment of inflammatory brain diseases, because the exosomes have outstanding therapeutic effects, including inhibiting cell death due to inflammation in nerve cells, increasing the survival rate in an inflammatory-brain-disease animal model, and substantially reducing brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema.

Abstract: A catalytic converter for a vehicle includes an LNT converter into one side of which exhaust gas discharged from an engine flows and from the opposite side of which the exhaust gas. The LNT converter traps nitrogen oxide contained in the exhaust gas under a lean environment, desorbs the trapped nitrogen oxide under a rich environment, and reduces the nitrogen oxide contained in the exhaust gas or the desorbed nitrogen oxide. A connecting housing changes a direction of a path of the exhaust gas to a vertical direction, and allows a reducing agent to be injected to the exhaust gas. An SDPF converter changes a direction of a path of the exhaust gas to a direction opposite to a direction, captures particulate matters contained in the exhaust gas, and reduces nitrogen oxide contained in the exhaust gas using the injected reducing agent.

Abstract: A method of desulfurizing a lean NOx trap (LNT) of an exhaust purification system provided with the LNT and a selective catalytic reduction (SCR) catalyst includes determining whether a desulfurization feasibility condition of the LNT is satisfied, determining whether a desulfurization demand condition of the LNT is satisfied, and performing desulfurization of the LNT if both of the desulfurization feasibility condition of the LNT and the desulfurization demand condition of the LNT are satisfied, wherein the desulfurization of the LNT is performed by repeating a desulfurization lean mode and a desulfurization rich mode according to whether a mode switching condition due to a desulfurization temperature is satisfied and whether a mode switching condition due to generation of H2S is satisfied.

Abstract: Disclosed is a composition for the prophylaxis or therapy of intraventricular hemorrhage in preterm infants comprising mensenchymal stem cells. Functioning to prevent ventricular dilatation and reduce the level of inflammatory cytokines in cerebrospinal fluid, the composition comprising mesenchymal stem cells is advantageously useful for the prophylaxis or therapy of intraventricular hemorrhage in preterm infants. Accordingly, the composition is effectively preventive of hydrocephalus which occurs subsequent to intraventricular hemorrhage. In addition, the composition makes not only a histological and biochemical recuperation in the intraventricular hemorrhage-injured brain, but also significantly improves sensory motor functions. Mesenchymal stem cells can be used as an effective therapeutic agent because they are less prone to induce immune rejection responses and are highly likely to secrete proliferative, differentiative, and regulatory factors.

Abstract: A sealed honeycomb structure may include porous walls dividedly forming inlet cells and outlet cells extending from an end surface of an inlet side to an end surface of an outlet side, an outlet side sealing portion, and an inlet side sealing portion, wherein at least one outlet cell is a reinforced cell, where a reinforced part for reinforcing the outlet cell is formed at at least one corner portion at which the walls on a cross-section vertical to an extending direction of the cell cross each other, and wherein the inlet cell is a non-reinforced cell where the reinforced part is not formed at all the corner portions at which the walls on the cross-section vertical to the extending direction of the cell cross each other.

Abstract: The present disclosed provides a post-processing system of a diesel vehicle in which an LNT catalyst and a DPF are sequentially disposed on an exhaust gas channel of the engine. The post-processing system includes: an LNT catalyst configured to adsorb nitrogen oxide (NOx) under lean atmosphere and desorb the nitrogen oxide (NOx) under rich atmosphere, based on a window of theoretical air-fuel ratio; and a diesel particulate filter (DPF). The DPF includes a first purifier disposed at a back end of the LNT catalyst and purifying hydrocarbon (HC) and carbon monoxide (CO), and a second purifier disposed at a back end of the first purifier and purifying hydrogen sulfide (H2S).

Abstract: There is provided a method of treating lung diseases including administering cells separated or proliferated from umbilical cord blood to a patient suffering from such diseases.

Abstract: The present invention relates to a method of promoting generation of exosomes from stem cell by using thrombin. The method according to the present invention has superior effects of promoting generation of stem cell-derived exosomes and thus exosomes can be more efficiently obtained thereby compared to conventionally known methods. In addition, the method can be useful for related research.

Abstract: The present invention relates to a pharmaceutical composition for treating cerebrovascular diseases including stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention have superior nerve cell protective effects, such as inhibition of cerebral ventricular distention, reduction of hydrocephalus, and inhibition of nerve cell death and cellular inflammation in an intraventricular hemorrhage (IVH) animal model, and thus, can be useful in treating cerebrovascular diseases including intraventricular hemorrhage, etc.

Abstract: A sealed honeycomb structure which can suppress increase of pressure loss and improve durability favorably is disclosed. A sealed honeycomb structure 100 including includes a honeycomb structure having porous walls dividedly forming inlet cells and outlet cells, an outlet side sealing portion, and an inlet side sealing portion, wherein an opening area of the inlet cell is larger than an opening area of an outlet cell on a cross-section of the honeycomb structure, wherein at least one outlet cell is a reinforced cell where a reinforcing part for reinforcing the outlet cell is formed at at least one corner portion at which the walls on a cross-section vertical to an extending direction of the cell cross each other, and wherein the inlet cell is a non-reinforced cell where the reinforcing part is not formed at all the corner portions at which the walls on the cross-section vertical to the extending direction of the cell cross each other.